Investment analysts at BMO Capital Markets initiated coverage on shares of ObsEva (NASDAQ:OBSV) in a research note issued to investors on Monday. The brokerage set an “outperform” rating and a $20.00 price target on the stock. BMO Capital Markets’ price objective would suggest a potential upside of 97.63% from the company’s current price.
Other research analysts also recently issued reports about the stock. HC Wainwright set a $27.00 price objective on shares of ObsEva and gave the company a “buy” rating in a research report on Wednesday, August 16th. Leerink Swann restated an “outperform” rating and set a $18.00 price objective on shares of ObsEva in a research report on Wednesday, August 16th. Royal Bank Of Canada reiterated a “buy” rating and set a $22.00 price target on shares of ObsEva in a report on Thursday, November 2nd. Finally, Zacks Investment Research upgraded shares of ObsEva from a “sell” rating to a “hold” rating in a report on Friday, September 8th. Seven research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus target price of $19.00.
Shares of ObsEva (NASDAQ OBSV) traded down $0.03 on Monday, reaching $10.12. 27,559 shares of the company’s stock traded hands, compared to its average volume of 45,073. ObsEva has a 1-year low of $5.00 and a 1-year high of $14.69.
Several large investors have recently made changes to their positions in the company. Iguana Healthcare Management LLC increased its holdings in shares of ObsEva by 66.7% during the third quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock worth $407,000 after buying an additional 20,000 shares in the last quarter. Abingworth LLP acquired a new position in shares of ObsEva during the third quarter worth $3,480,000. VHCP Management II LLC increased its holdings in shares of ObsEva by 834.2% during the third quarter. VHCP Management II LLC now owns 1,401,343 shares of the company’s stock worth $11,407,000 after buying an additional 1,251,343 shares in the last quarter. Sphera Funds Management LTD. increased its holdings in shares of ObsEva by 12.4% during the third quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock worth $2,118,000 after buying an additional 28,700 shares in the last quarter. Finally, Sectoral Asset Management Inc increased its holdings in shares of ObsEva by 181.9% during the second quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after buying an additional 137,331 shares in the last quarter. Institutional investors own 35.91% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “BMO Capital Markets Initiates Coverage on ObsEva (OBSV)” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/04/bmo-capital-markets-initiates-coverage-on-obseva-obsv.html.
ObsEva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.